Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.

BACKGROUND Objective was to determine maximum tolerated dose (MTD), recommended dose (RD) and schedule, safety, pharmacokinetic (PK) profile, pharmacodynamic (PD) effects, and antitumor activity of Debio0932, a new second-generation oral heat shock protein (HSP) inhibitor. PATIENTS AND METHODS This was a multicenter, uncontrolled, open-label, nonrandomized, dose-escalation study in adults with treatment-resistant advanced cancer. Groups of three patients received oral Debio0932 either daily or every other day. The starting dose of 50 mg was escalated until the MTD was reached, i.e. dose-limiting toxicity (DLT) occurred in ≥2 patients. Further 9 patients and an extension cohort of 30 patients were treated at the next lower dose (=RD). Adverse events (AEs), tumor response, PK, and HSP70 levels in peripheral blood mononuclear cells were recorded over 30 days. RESULTS Fifty patients were treated with doses up to 1600 mg, at which level three DLT occurred (febrile neutropenia, diarrhea, asthenia). In total, 39 patients were then treated at the RD of 1000 mg daily. Most common drug-related AEs were asthenia and gastrointestinal events. No ocular toxicities were observed. Debio0932 was rapidly absorbed and metabolized. Plasma steady state was reached within 9 days. Volume of distribution was high and elimination half-life was 9-11 h. Food had no effect on PK. PD showed large interpatient variability, but no dose-effect relationship. Partial tumor response was observed in 2 patients (NSCLC and breast cancer), stable disease (SD) in 12 patients (5 of 8 NSCLC patients). In the extension cohort, 9 patients had SD, and 1 patient a partial metabolic tumor response. CONCLUSION Debio0932 has limited clinical activity, together with manageable toxicity. Further development as adjunct treatment of NSCLC at daily doses of 1000 mg is warranted. CLINICAL TRIAL NCT01168752.

[1]  E. Laurini,et al.  Abstract 953: Novel inhibitors of signal transducer and activator of transcription 3 (STAT3) show potent activity in cell cultures and tumor xenografts , 2014 .

[2]  Ho-June Lee,et al.  Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.

[3]  S. Hayashi,et al.  Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs. , 2014, The Journal of toxicological sciences.

[4]  R. Bates,et al.  A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors. , 2013, Toxicology and applied pharmacology.

[5]  E. Lee,et al.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. , 2012, The New England journal of medicine.

[6]  B. Blagg,et al.  The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. , 2012, Molecular pharmaceutics.

[7]  S. Mustjoki,et al.  Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.

[8]  H. Too,et al.  Mitochondrial Localized STAT3 Is Involved in NGF Induced Neurite Outgrowth , 2011, PloS one.

[9]  Alison Stopeck,et al.  HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab , 2011, Clinical Cancer Research.

[10]  G. Giaccone,et al.  Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. , 2010, European journal of cancer.

[11]  Xiong Cai,et al.  Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer , 2009, Molecular Cancer Therapeutics.

[12]  A. Ventura,et al.  Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer. , 2009, Cancer research.

[13]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[14]  P. Fawcett,et al.  Function of Mitochondrial Stat3 in Cellular Respiration , 2009, Science.

[15]  P. Yue,et al.  Targeting STAT3 in cancer: how successful are we? , 2009, Expert opinion on investigational drugs.

[16]  Xiong Cai,et al.  Cancer Therapy : Preclinical CUDC-305 , a Novel Synthetic HSP 90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy , 2009 .

[17]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[18]  Sarat Chandarlapaty,et al.  SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers , 2008, Clinical Cancer Research.

[19]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[20]  P. Workman,et al.  Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. , 2006, Endocrine-related cancer.

[21]  M. Meyerson,et al.  Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. , 2006, Cancer research.

[22]  D. Solit,et al.  Hsp90: the vulnerable chaperone. , 2004, Drug discovery today.

[23]  N. Rosen,et al.  Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. , 2004, Chemistry & biology.

[24]  A. Kamal,et al.  Therapeutic and diagnostic implications of Hsp90 activation , 2004, Trends in Molecular Medicine.

[25]  R. Morimoto,et al.  Molecular chaperones and the stress of oncogenesis , 2004, Oncogene.

[26]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[27]  N. Rosen,et al.  Development of purine-scaffold small molecule inhibitors of Hsp90. , 2003, Current cancer drug targets.

[28]  P. Workman,et al.  The clinical applications of heat shock protein inhibitors in cancer - present and future. , 2003, Current cancer drug targets.

[29]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[30]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[31]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[32]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  F. Hartl,et al.  In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis , 1998, The Journal of cell biology.